GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...

This Collection invites original research articles on phase contrast imaging, looking at the latest technological developments and the use of this technique in original applications. Phase contrast ...

Techniques that exploit the phase of X-rays, not just their absorption, have the potential to transform X-ray imaging in hospitals, reports Jude Dineley Improved imaging Marian Willner from the ...

MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...

MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating ...

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...